[1] Reuben A, Koch D G, Lee W M, et al. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepa-tology, 2010, 52: 2065-2076.
[2] Licata A, Puccia F, Lombardo V, et al. Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. Eur J Gastroenterol Hepatol, 2018, 30: 226-232.
[3] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 临床肝胆病杂志, 2015, 31: 1752-1769.
[4] 黄志强. 希夫肝脏病学(M). 化学工业出版社, 2004, 947-948.
[5] 姚光弼,陈成伟. 药物与中毒性肝病. 上海科学技术出版社, 2002, 88-89.
[6] 任张青, 王进海, 郭晓燕等. 2005-2014年我国药物性肝损伤临床综合分析. 药物流行病学杂志, 2016, 25: 284-289.
[7] Raschi E, De Ponti F. Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World J Hepatol, 2015, 7: 1761-1771.
[8] Liakoni E, Ratz Bravo A E, Krahenbuhl S. Hepatotoxicity of New Oral Anticoagulants (NOACs). Drug Saf, 2015, 38: 711-720.
[9] Russo M W, Galanko J A, Shrestha R, et al. Liver transp-lantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl, 2004, 10: 1018-1023. |
